Future Journal of Pharmaceutical Sciences最新文献

{"title":"Postoperative pain management following laparoscopic cholecystectomy-non-opioid approaches: a review","authors":"Hoda Mohamed Bayoumi,&nbsp;Doaa Hamed Abdelaziz,&nbsp;Nouran Omar El Said,&nbsp;Sherif Boraii,&nbsp;Ehab Rasmy Bendas","doi":"10.1186/s43094-024-00697-z","DOIUrl":"10.1186/s43094-024-00697-z","url":null,"abstract":"<div><h3>Background</h3><p>Gallstone disease with its consequences is a common clinical issue that may necessitate surgical removal. In comparison with traditional open procedures, laparoscopic cholecystectomy (LC) remains the mainstay treatment for symptomatic gallstone disease and can lead to a shorter recovery period, and a shorter hospital stay; yet, severe abdominal and shoulder pain may be experienced.</p><h3>Main body</h3><p>Novel drugs and technology for acute and chronic pain management following LC have been studied to improve patient care. The review discusses innovative pain management strategies with non-opioid approaches for laparoscopic surgery, with an emphasis on ensuring speedy and safe recovery.</p><h3>Conclusion</h3><p>The key findings state that IV paracetamol is a necessary part of multimodal postoperative pain management. There were several pharmacological interventions found to be effective in pain control: magnesium sulfate and dexamethasone showed anti-inflammatory benefits; ondansetron provided analgesic effects; gabapentinoids and alpha-2-agonists reduced central sensitization; local anesthetics offered targeted pain relief; antidepressants addressed neuropathic pain; NSAIDs proved effective for inflammatory pain. Similarly, non-pharmacological approaches, and emerging technologies, also contributed to the management of post-LC pain underscoring the need for a comprehensive approach to its management. More rigorous research is needed to guide pain management after LC. Future studies should compare multiple treatments simultaneously and involve larger patient groups. This approach will help identify optimal pain control strategies. It will also provide clearer insights into the safety and efficacy of various pain medications under comparable clinical conditions.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00697-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multichannel 3D-printed bionanoparticles-loaded tablet (M3DPBT): designing, development, and in vitro functionality assessment","authors":"Hardik Rana,&nbsp;Priyanka Pathak,&nbsp;Vimal Patel,&nbsp;Vaishali Thakkar,&nbsp;Mansi Dholakia,&nbsp;Saloni Dalwadi,&nbsp;Tejal Gandhi","doi":"10.1186/s43094-024-00702-5","DOIUrl":"10.1186/s43094-024-00702-5","url":null,"abstract":"<div><h3>Background</h3><p>The intersubject variability which was related to the genetic makeup was the major cause of change in pharmacological and pharmacokinetic behavior of same dosage form in varied human being. 3D printing technology will help therapy evolve and eliminate the limitations of conventional technologies. Nebivolol's (NBL)-limited oral bioavailability is mainly due to its poor aqueous solubility. The research aims to combine advanced 3D printing technology and nanotechnology to design customized therapy and enhance the functionality of NBL using a statistical approach.</p><h3>Results and discussion</h3><p>The results of the phase solubility indicated that NBL was a poorly aqueous soluble drug. Its solubility was increased by employing nanoparticle drug delivery, which is a promising solubility enhancement technique. The 3² full factorial design was employed to develop and optimize bionanoparticles (BNPs) by solvent evaporation technique using poly (lactic-co-glycolic acid 50:50) (PLGA 50:50) and poloxamer-407 as a surfactant. The BNPs were characterized by % encapsulation efficiency (% EE), Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimeter (DSC), transmission electron microscope (TEM), zeta potential, polydispersity index (PDI), particle size, in vitro drug release, etc. The BNPs loaded of NBL were further incorporated into the multichannel 3D-controlled release tablets made by PVA filaments employing fused deposition modeling (FDM) technology optimized by central composite design (CCD). Multichannel 3D-printed bionanoparticles-loaded tablet (M3DPBT) was optimized using CCD. All designed M3DPBTs were evaluated for post-fabrication parameters. The optimized M3DPBT could release more than 85% NBL within 10 h.</p><h3>Conclusions</h3><p>The newly fabricated M3DPBT was found stable. The amount of PLGA 50:50 and Polaxomer was significant for developing BNPs. % infill and layer height were observed as critical for the designing M3DPBT. The combined novel 3D printing and nanotechnology technology will open a new direction for patient compliance and better therapeutic effects.</p><h3>Graphical abstract</h3><p>Designing and developing of M3DPBT is substantially improve the patient compliance and therapeutic effectiveness of Nebivolol.</p>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00702-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality characteristics and HPLC detection of phosphodiesterase inhibitors in some herbal capsules indicated for male sexual disorders in Ghana","authors":"Anita Nana Abla Oscar Akotey,&nbsp;Isaac Kingsley Amponsah,&nbsp;Francis Ackah Armah,&nbsp;Bernard Kofi Turkson,&nbsp;John Nii Addotey,&nbsp;Yaa Asantewaa Osei,&nbsp;Joseph Adu,&nbsp;Rita Akosua Dickson","doi":"10.1186/s43094-024-00693-3","DOIUrl":"10.1186/s43094-024-00693-3","url":null,"abstract":"<div><h3>Background</h3><p>Herbal medicines used for male sexual disorders are widespread across the globe and have been noted as likely candidates for adulteration. To assure access to safe and quality herbal products, this study aimed at sampling some herbal capsules indicated for male vitality for quality analytical checks.</p><h3>Methods</h3><p>Herbal capsules sampled from two regions were subjected to physicochemical assessment, using pharmacopeial and regulatory standards. Microbial quality analysis was also performed on the selected products. A validated HPLC method for simultaneous analysis of sildenafil citrate and tadalafil was used to detect and quantify the possible presence of phosphodiesterase inhibitors in the selected products.</p><h3>Results</h3><p>Out of a total of 57 herbal capsules, 19 were indicated for male sexual related illnesses of which only 8 fulfilled the inclusion criteria of being used exclusively for male vitality. The majority (62.5%) of the herbal products failed the weight uniformity test but all of them disintegrated within the acceptable limit of 30 min. The moisture and heavy metal contents were within limits of acceptability. Majority (87.5%) of the herbal products failed the test for the aerobic bacteria count; however, none of the isolated bacteria was pathogenic. Sildenafil citrate was detected in the majority (87.5%) of the herbal products in concentrations of 0.98–33.95 mg/g. Two products contained both sildenafil and tadalafil. High batch-to-batch variability was recorded in some physicochemical parameters and pharmaceutical adulterants.</p><h3>Conclusion</h3><p>High incidence of quality fails and adulteration of herbal capsules for sexual disorders observed means there is a real risk of unintended dosing with phosphodiesterase inhibitors. This represents a public health issue and necessitates tighter monitoring of production standards by the regulator.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00693-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LC–MS/MS-QTOF analysis of Anodendron parviflorum (Roxb.) leaves extract and exploring its antioxidant, antimicrobial, and cytotoxic potential","authors":"Arunagiri Sharmila,&nbsp;Chinnadurai Immanuel Selvaraj","doi":"10.1186/s43094-024-00695-1","DOIUrl":"10.1186/s43094-024-00695-1","url":null,"abstract":"<div><h3>Background</h3><p>Traditional medicine claims that <i>Anodendron parviflorum</i> has benefits for treating various human diseases. The present study seeks to understand better the phytochemical and LC–MS/MS-QTOF profiling of <i>A. parviflorum</i>'s ethanolic extract and to investigate the properties of the different solvents of <i>A. parviflorum</i> for anti-inflammatory, antioxidant, antimicrobial, toxicity, and cytotoxic effects.</p><h3>Results</h3><p>The quantitative methods exhibited higher total phenolics (327.16 ± 2.4 mg GAE/g dw), total flavonoid (109.82 ± 1.9 mg QE/g dw), and total alkaloid (14.13 ± 0.09%) content in ethanol extract. In contrast, a higher total extraction value (22.8 ± 0.6%) and total terpenoid (57.23 ± 0.06 mg LL/g dw) content was shown in the methanol extract of <i>A. parviflorum</i>. LC–MS/MS-QTOF analysis of its ethanolic extract revealed a notable occurrence of phenols and flavonoids. The ethanolic extract of <i>A. parviflorum</i> exhibited significant antioxidant activities with lower IC₅₀ values in DPPH, phosphomolybdenum, and metal chelating and reducing power assay. The methanolic extract of <i>A. parviflorum</i> had the more significant anti-inflammatory property (94.55 ± 0.1%) in the bovine serum albumin assay. The extracts also demonstrated a higher inhibition zone against pathogenic bacteria. The ethanolic extract of <i>A. parviflorum</i> demonstrated substantial cytotoxicity against A549 cells.</p><h3>Conclusion</h3><p>Consequently, these findings validate the use of <i>A. parviflorum</i> in traditional medical practices due to its bioactive compounds, which may have potential therapeutic value in various biomedical applications.</p><h3>Highlights</h3>\u0000<ul>\u0000 <li>\u0000 <p><i>A. parviflorum</i> leaves extract showed the presence of significant levels of alkaloids, flavonoids, phenols, and terpenoids.</p>\u0000 </li>\u0000 <li>\u0000 <p>LC–MS/MS-QTOF analysis revealed notable bioactive compounds of <i>A. parviflorum.</i></p>\u0000 </li>\u0000 <li>\u0000 <p>The different extracts showed remarkable antioxidant and antimicrobial activities.</p>\u0000 </li>\u0000 <li>\u0000 <p>The extracts exhibited less hemolytic and higher thrombolytic activities.</p>\u0000 </li>\u0000 <li>\u0000 <p>It demonstrated significant cytotoxicity against A549 cell lines.</p>\u0000 </li>\u0000 </ul><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00695-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142169813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholecalciferol effect on oxidative stress and novel predictors of inflammation in hemodialysis patients: a prospective randomized trial","authors":"Mona Alshahawey,&nbsp;Lamia Mohamed El Wakeel,&nbsp;Tamer Wahid Elsaid,&nbsp;Nagwa Ali Sabri,&nbsp;Radwa Maher Elborolossy","doi":"10.1186/s43094-024-00696-0","DOIUrl":"10.1186/s43094-024-00696-0","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence links vitamin D deficiency to oxidative stress (OS) and inflammation, posing ongoing risks to cardiovascular outcomes in hemodialysis (HD) patients. Despite this, current data are lacking regarding the optimal approach or schedule for administering vitamin D in this population. This study investigated the effectiveness of oral weekly versus oral monthly cholecalciferol supplementation on 25-hydroxy vitamin D (25(OH)D) levels, oxidative stress, inflammatory indicators, and secondary hyperparathyroidism in HD population. HD patients (<i>N</i> = 50) were randomly allocated to Group A (oral weekly 50,000 IU cholecalciferol) or Group B (oral monthly 200,000 IU cholecalciferol) for a 3 months duration. Serum levels of 25(OH)D, malondialdehyde (MDA), superoxide dismutase (SOD), high sensitivity C-reactive protein (HsCRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and intact parathyroid hormone (iPTH) were assessed at baseline and upon completion of the study.</p><h3>Results</h3><p>A notable increase in serum 25(OH)D levels observed in both groups, with Group A showing a notably greater increase (<i>p</i> = 0.003). Group A demonstrated significant reductions in serum MDA and increases in SOD, along with declines in hsCRP and NLR levels, which were not observed in Group B. Moreover, Group A exhibited a greater drop in iPTH (ΔiPTH = − 30 pg/mL vs. − 3 pg/mL) compared to Group B. Clinicaltrial.gov: NCT05460338, registered 13/07/2022.</p><h3>Conclusions</h3><p>Weekly oral 50,000 IU cholecalciferol supplementation emerges as a tolerable, safe and effective approach for restoring vitamin D levels in HD patients, while concurrently mitigating inflammation, OS, and secondary hyperparathyroidism. This finding suggests that the more frequent the administration of oral cholecalciferol, the higher the efficiency observed.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00696-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)","authors":"Merusomayajula V. Kishore,&nbsp;T. Siva Rao,&nbsp;G. N. D. Kumari","doi":"10.1186/s43094-024-00685-3","DOIUrl":"10.1186/s43094-024-00685-3","url":null,"abstract":"<div><h3>Background</h3><p>Since December 2019, a global crisis has unfolded with the emergence of a new strain of coronavirus known as SARS-CoV-2. This pandemic has afflicted hundreds of millions of people worldwide, resulting in millions of fatalities. In response to this urgent healthcare crisis, extensive efforts have been made to discover inhibitors of the COVID-19 virus. Given the structural similarities between SARS-CoV-2 and HCV, drugs approved by the FDA for treating HCV were selected and subjected to in silico testing against the SARS-CoV-2 virus, with Remdesivir used as the standard for validation. Drug repurposing and phytochemical testing have also been conducted to identify potential candidates capable of inhibiting or suppressing the infection caused by the coronavirus. The time constraints imposed by the pandemic necessitated the in silico analysis of existing drug molecules against the coronavirus. Eleven HCV drugs approved by the FDA, along with one RNA synthesis inhibitor antibiotic drug, were tested using the in silico method due to their structural similarities with HCV and the SARS-CoV-2 virus.</p><h3>Results</h3><p>Molecular docking and MD simulation studies were performed for all selected compounds. Binding energies, root-mean-square deviation, root-mean-square fluctuation, solvent-accessible surface area, radius of gyration, and molecular mechanics generalized born surface area were calculated. Based on docking and MD simulation studies all the selected compounds have shown good binding energy values with Mpro (PDB ID: 6LU7). No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA.</p><h3>Conclusions</h3><p>This study shows that FDA-approved HCV drugs can be used as for SARS-COVID-19 inhibitors.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00685-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep eutectic solvent strategy for green extraction of chlorogenic acid from sea buckthorn: optimization and sustainability","authors":"Iqra Saddique,&nbsp;Sumia Akram,&nbsp;Saima Rubab,&nbsp;Ayesha Sadiqa,&nbsp;Ali Raza,&nbsp;Muhammad Mushtaq,&nbsp;Mohsin Ahmad Ghauri","doi":"10.1186/s43094-024-00699-x","DOIUrl":"10.1186/s43094-024-00699-x","url":null,"abstract":"<div><h3>Background</h3><p>Sea buckthorn (<i>Hippophae rhamnoides</i>), a deciduous species plant, is widely distributed around the globe, and native to the cold-temperate regions of Europe and Asia. This medicinal herb contains several bioactive constituents including chlorogenic acid. The conventional methods used for the extraction of phenolic antioxidants from natural herbs often result in low yields, high toxicity, and pose environmental hazards limiting their effectiveness and scalability. Therefore, green extraction techniques using deep eutectic solvents, composed of natural, non-toxic, and biodegradable components were applied for extraction of chlorogenic acid from sea buckthorn weed. Fourteen deep eutectic solvent mixtures were prepared and evaluated for extraction yield of chlorogenic acid. Parameters such as hydrogen bond donor-to-hydrogen bond acceptor ratio, liquid-to-solid ratio, shaking speed, and shaking time were optimized for the best mixture.</p><h3>Results</h3><p>The combination of lactic acid and maltose (1:1) was found to give best extraction yield using response surface methodology. The deep eutectic solvent system under optimum conditions produced 12.2 g/100 g of crude extract sea buckthorn containing 174.7 mg gallic acid equivalents (mg GA)/g) of extract. Moreover, the optimized extract exhibited appreciable radical scavenging capacity (91%), trolox equivalent antioxidant capacity (11.2% of extract), and inhibition of peroxide in linoleic acid (80.6%). High-performance liquid chromatography-based characterization revealed the extracts contained chlorogenic acid (20.1 mg/g of extract) as the major constituent.</p><h3>Conclusions</h3><p>In summary, the adoption of DES for the extraction of bioactive phenolic constituents from sea buckthorn offers multiple benefits, including economic efficiency, enhanced extraction performance, and environmental sustainability. The findings of this study not only advance the understanding of DES in phytochemical extraction but also pave the way for broader application of green solvents in the natural products industry. Future research should focus on further optimizing DES formulations and scaling up the extraction process to fully realize the potential of this innovative extraction method in commercial applications.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00699-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemical comparison of selected Sida species using spectrophotometric and multiple chromatographic analyses","authors":"Cheruthazhakkat Sulaiman,&nbsp;Ankitha Saji,&nbsp;Erayur Mana Anandan,&nbsp;Indira Balachandran","doi":"10.1186/s43094-024-00692-4","DOIUrl":"10.1186/s43094-024-00692-4","url":null,"abstract":"<div><h3>Background</h3><p>Bala is an important Ayurvedic drug used for the treatment of many diseases. <i>Sida cordifolia</i> (L.), Malvaceae family, is the genuine source drug of Bala as per Ayurvedic Pharmacopeia of India. The other species of Sida like <i>Sida acuta</i>, <i>Sida rhombifolia</i>, <i>Sida alnifolia</i> and <i>Sida cordata</i> are also used as adulterants or substitutes of Bala. The objective of the present study is to identify a scientifically validated substitute for Bala (<i>Sida cordifolia</i>) by detailed phytochemical evaluation of its allied species.</p><h3>Results</h3><p>Preliminary analysis showed that all the selected species contain similar class of compounds like alkaloids, phenolics, flavonoids, etc. Quantitative estimation of major class of compounds such as total alkaloids, total phenolics and total flavonoids was done by spectrophotometric methods. Polyphenolic contents of selected species are almost comparable. In the case of alkaloids, variations have been observed among the species. Chemical profiles of selected species were compared by HPTLC and HPLC analysis. Major chemical constituents are found to be common for the selected species. HPLC profiles also showed similarity in their peak pattern.</p><h3>Conclusion</h3><p>Based on the phytochemical studies, the species like <i>S. alnifolia</i>, <i>S. acuta</i> and <i>S. rhombifolia</i> contain almost similar types of phytochemicals. However, the chemical constituents of <i>Sida cordata</i> are found to be different from other allied species. Further studies including pharmacological evaluation are required to ensure the therapeutic properties of allied species to confirm the substitute.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00692-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Citrus aurantifolia-derived carbon quantum dots with red fluorescence emission for codelivery with curcumin as theranostic liposomes for lung cancer","authors":"Angshuman Sonowal,&nbsp;Alakesh Bharali,&nbsp;Trideep Saikia,&nbsp;Susankar Kushari,&nbsp;Madhuchandra Lahon,&nbsp;Jun Moni Kalita,&nbsp;Nikhil Biswas,&nbsp;Damiki Laloo,&nbsp;Bhanu P. Sahu","doi":"10.1186/s43094-024-00689-z","DOIUrl":"10.1186/s43094-024-00689-z","url":null,"abstract":"<div><h3>Background</h3><p>Carbon dots (CDs) derived from <i>Citrus aurantifolia</i> represent a promising platform for advanced cancer therapy and diagnostics (theranostics). These CDs are synthesized through a sustainable and cost-effective hydrothermal method, utilizing fruit juice as a green carbon source. Despite the potential, research on the synthesis of citrus-based CDs, especially regarding their red fluorescence emission, which is crucial for enhanced tissue penetration and biomedical efficacy, remains limited.</p><h3>Results</h3><p>In this study, CDs were successfully synthesized from <i>C</i>. <i>aurantifolia</i> fruit, yielding nanoparticles below 5 nm in size (PDI 0.231 ± 0.04). Characterization revealed favorable optical properties, including excitation-dependent fluorescent behavior with prominent red emission under higher excitation wavelengths, a quantum yield of 8.17%, and stable photoluminescence. Chemical composition analysis using XPS, FTIR, and XRD confirmed the purity and structure of the CDs.</p><p>To explore their biomedical application, CDs were co-loaded with curcumin into liposomes. The formulations had a mean size of 177.2 ± 3.6 nm (PDI 0.270 ± 0.012), demonstrated efficient drug entrapment (60.32 ± 2.24%), and exhibited rapid release kinetics, with 90.21 ± 2.16% of the drug release within 8 h. In vitro studies using A549 lung cancer cells demonstrated superior cellular uptake and cytotoxicity of Cur-CD-loaded liposomes compared to curcumin alone (Cur-Suspension), achieving IC50 values of 0.093 ± 0.011 µg/ml and 0.016 ± 0.006 µg/ml, respectively.</p><h3>Conclusion</h3><p>This research underscores <i>C</i>. <i>aurantifolia</i> as a viable natural source for green CD synthesis. The obtained CDs with red fluorescence emission, optimized through reaction conditions and excitation wavelengths, hold promise for enhanced biological applications, particularly in the realm of lung cancer therapy. The findings advocate for further exploration and refinement of citrus-based CDs as versatile theranostic agents, capitalizing on their sustainable origins and potent biomedical properties. The combination of citrus-derived CDs with curcumin loaded into liposomal formulations represents a potent theranostic strategy for lung cancer treatment, leveraging the unique properties of CDs and their potential for targeted and effective therapy.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00689-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142130326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation of empty cell envelopes of Streptococcus pyogenes using biosurfactants","authors":"Amany Abdelfattah,&nbsp;Heba M. Amin,&nbsp;Sameh Rabea,&nbsp;Reham Samir","doi":"10.1186/s43094-024-00664-8","DOIUrl":"10.1186/s43094-024-00664-8","url":null,"abstract":"<div><h3>Background</h3><p>Bacterial ghost cells (BGCs) are cell envelopes that devoid of cytoplasmic and genetic contents in purpose of variable applications, including their great potential as vaccine candidates and their effectiveness as delivery systems for drugs and proteins. To our knowledge, this is the first study to produce Gram-positive BGCs by treating <i>Streptococcus pyogenes</i> (<i>S. pyogenes</i>) ATCC 19615 with Tween80 (TW80) or TritonX-100 (TX100), followed by preliminary testing of their antigenicity and safety in NIH/Ola-Hsd mice. The produced BGCs were confirmed by the presence of intact cells under a light microscope, the absence of growth signs upon re-cultivation. The transmembrane tunnels were visualized using a scanning electron microscope, and subsequently, considerable quantities of released DNA and protein were detected in the culture supernatant of the BGCs. The antigenicity of the produced BGCs was tested through three intra-nasal immunization doses followed by infection. Afterward, the opsonic activity and the IgG levels were measured, followed by a comprehensive histopathological examination for selected tissues and organs.</p><h3>Results</h3><p>The sera of immunized mice exhibited a significant rise in both opsonic activity (TW80 produced BGC = 68% and TX100 produced BGC = 75%) and IgG levels (TW80 produced BGC = a threefold increase and TX100 produced BGC = a fourfold increase) when compared to the positive control group \"non-immunized challenged with ATCC 19615.\" Histopathological analysis revealed that the BGCs produced by TW80 are relatively safer and have a less severe impact than those produced by TX100.</p><h3>Conclusion</h3><p>The study's findings suggest that <i>Sp</i>-BGC/TW80 is initially effective and safe in vivo. However, further pre-clinical studies are necessary to confirm its effectiveness and ensure complete safety, specifically in terms of the absence of autoimmunity and antibody cross-reactivity with myosin proteins in human cardiac tissues.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00664-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142123083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}